Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer

Virchows Archiv

Volumn 462, Issue 1, 2013, Pages 65-72

  Ach, Tobias ^a   Zeitler, Katharina ^a   Schwarz Furlan, Stephan ^b   Baader, Katharina ^a   Agaimy, Abbas ^b   Rohrmeier, Christian ^a   Zenk, Johannes ^b   Gosau, Martin ^a   Reichert, Torsten E ^a   Brockhoff, Gero ^a   Ettl, Tobias ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

EGFR; MET; Prognosis; PTEN; Salivary gland cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SCATTER FACTOR RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CHILD; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENOME; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LONG TERM SURVIVAL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SALIVARY GLAND CANCER; SCHOOL CHILD; SEX DIFFERENCE; TUMOR VOLUME;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; DNA COPY NUMBER VARIATIONS; DNA, NEOPLASM; FEMALE; GENE DOSAGE; GERMANY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SALIVARY GLAND NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

EID: 84872298896     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-012-1358-0     Document Type: Article

References (43)

1. Speight PM, Barrett AW (2002) Salivary gland tumours. Oral Dis 8:229-240
2. Hara T, Ooi A, Kobayashi M et al (1998) Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization. Lab Invest 78:1143-1153
3. Masuya D, Huang C, Liu D et al (2004) The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients. Br J Cancer 90:1555-1562
4. Miller CT, Lin L, Casper AM et al (2006) Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene 25:409-418
5. Birchmeier C, Birchmeier W, Gherardi E et al (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915-925
6. Engelman JA, Zejnullahu K, Mitsudomi T et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043
7. Barnes L, Eveson JW, Reichart P et al (2005) Pathology and genetics of head and neck tumours. World Health Organization Classification of Tumours. IARC Press, Lyon, p 430
8. Jouzdani E, Yachouh J, Costes V et al (2010) Prognostic value of a three-grade classification in primary epithelial parotid carcinoma: result of a histological review from a 20-year experience of total parotidectomy with neck dissection in a single institution. Eur J Cancer 46:323-331
9. Therkildsen MH, Christensen M, Andersen LJ et al (1998) Salivary gland carcinomas - prognostic factors. Acta Oncol 37:701-713
10. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403-410
11. Schwarz S, Stiegler C, Muller M et al (2011) Salivary gland mucoepidermoid carcinoma is a clinically, morphologically and genetically heterogeneous entity: a clinicopathological study of 40 cases with emphasis on grading, histological variants and presence of the t(11;19) translocation. Histopathology 58:557-570
12. Cappuzzo F, Hirsch FR, Rossi E et al (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643-655
13. Cappuzzo F, Janne PA, Skokan M et al (2009) MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol 20:298-304
14. Ettl T, Stiegler C, Zeitler K et al (2012) EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis. Hum Pathol 43:921-931
15. Ettl T, Baader K, Stiegler C et al (2012) Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. Br J Cancer 106:719-726
16. Cooper CS, Park M, Blair DG et al (1984) Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311:29-33
17. Appleman LJ (2011) MET signaling pathway: a rational target for cancer therapy. J Clin Oncol 29:4837-4838
18. Lal B, Goodwin CR, Sang Y et al (2009) EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. Mol Cancer Ther 8:1751-1760
19. Suzuki S, Dobashi Y, Minato H et al (2012) EGFR and HER2-Akt-mTOR signaling pathways are activated in subgroups of salivary gland carcinomas. Virchows Arch 461:271-282
20. Williams MD, Roberts DB, Kies MS et al (2010) Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin Cancer Res 16:2266-2274
21. Takami T, Kaposi-Novak P, Uchida K et al (2007) Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N- nitrosodiethylamine induced hepatocarcinogenesis. Cancer Res 67:9844-9851
22. Dziadziuszko R, Wynes MW, Singh S et al (2012) Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer. J Thorac Oncol 7:340-347
23. Tsukinoki K, Yasuda M, Mori Y et al (2004) Hepatocyte growth factor and c-Met immunoreactivity are associated with metastasis in high grade salivary gland carcinoma. Oncol Rep 12:1017-1021
24. Suzuki K, Cheng J, Watanabe Y (2003) Hepatocyte growth factor and c-Met (HGF/c-Met) in adenoid cystic carcinoma of the human salivary gland. J Oral Pathol Med 32:84-89
25. Klosek SK, Nakashiro K, Hara S, Shintani S, Hasegawa H, Hamakawa H (2005) CD151 forms a functional complex with c-Met in human salivary gland cancer cells. Biochem Biophys Res Commun 336:408-416
26. Lennerz JK, Kwak EL, Ackerman A et al (2011) MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 29:4803-4810
27. Tanizaki J, Okamoto I, Okamoto K et al (2011) MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. J Thorac Oncol 6:1624-1631
28. Bean J, Brennan C, Shih JY et al (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104:20932-20937
29. Benedettini E, Sholl LM, Peyton M et al (2010) Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol 177:415-423
30. Arteaga CL (2007) HER3 and mutant EGFR meet MET. Nat Med 13:675-677
31. Cepero V, Sierra JR, Corso S et al (2010) MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res 70:7580-7590
32. Danilkovitch-Miagkova A, Zbar B (2002) Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest 109:863-867
33. Qi J, McTigue MA, Rogers A et al (2011) Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res 71:1081-1091
34. Li Y, Guessous F, DiPierro C et al (2009) Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy. Mol Cancer Ther 8:376-385
35. Frattini M, Saletti P, Romagnani E et al (2007) PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97:1139-1145
36. Mellinghoff IK, Wang MY, Vivanco I et al (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012-2024
37. Pandolfi PP (2004) Breast cancer - loss of PTEN predicts resistance to treatment. N Engl J Med 351:2337-2338
38. Agulnik M, Cohen EW, Cohen RB et al (2007) Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 25:3978-3984
39. Glisson BS, Blumenschein G, Francisco M et al (2005) Phase II trial on gefitinib in patients with incurable salivary gland cancer [abstract]. J Clin Oncol 23:5532
40. Haddad R, Colevas AD, Krane JF et al (2003) Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol 39:724-727
41. Locati LD, Bossi P, Perrone F et al (2008) Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 45:574-578
42. Vidal L, Tsao MS, Pond GR et al (2009) Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib. Head Neck 31:1006-1012
43. Piha-Paul SA, Cohen PR, Kurzrock R (2011) Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus. J Clin Oncol 29:e727-e730